Ingevity reported Q2 2025 earnings with mixed results: non-GAAP EPS exceeded expectations at $1.39, but revenue declined 6.5% to $365.1 million. The company saw improved profitability and cash flow, with a significant goodwill impairment in Advanced Polymer Technologies.

Ingevity Corporation reported a Q2 2024 loss of $283.7 million or $7.81 per share, down from a profit of $35.5 million a year ago. Revenues declined 18.9% year-over-year to $390.6 million, missing estimates. The company revised its sales and adjusted EBITDA guidance for 2024.

The article analyzes the recent ratings and price targets of 5 financial analysts for Ingevity, a chemical manufacturer. The analysts have a mixed outlook, with an average 12-month price target of $55.2 and a range of ratings from 'Outperform' to 'Underperform'. The company's financial performance, including declining revenue, low profitability, and high debt levels, are also discussed.

Ingevity Corporation has expanded its Capa caprolactone distribution network by selecting Ultrapolymers Group as the distributor for Capa Bioplastics in Europe. This move aligns with Ingevity's growth strategy in the region.

Ingevity Corp has finalized the termination of a significant crude tall oil supply agreement with GP Pine Chemicals, a subsidiary of Georgia-Pacific. The termination provides Ingevity more flexibility as it plans to restructure its Performance Chemicals business segment to focus on specialty chemicals markets.

Ingevity (NGVT) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Hawkins (HWKN) sees strong growth in the Water Treatment segment in the fiscal fourth quarter.

American Vanguard's (AVD) U.S. crop business registers strong sales of granular soil insecticides, herbicides and cotton and peanut products in Q1.

Strong results in the Performance Chemicals segment drove Innospec's (IOSP) earnings in Q1.

Valvoline's (VVV) fiscal second-quarter earnings and revenues surpass estimates on higher system-wide same-store sales.

Ingevity (NYSE:NGVT) underwent analysis by 4 analysts in the last quarter, revealing a spectrum of viewpoints from bullish to bearish. The table below offers a condensed view of their recent ratings, showcasing the changing sentiments over the past 30 days and comparing them to the preceding months. Bullish Somewhat Bullish Indifferent Somewhat Bearish Bearish Total Ratings 1 1 2 0 0 Last 30D 0 0 1 0 0 1M Ago 1 1 0 0 0 2M Ago 0 0 0 0 0 3M Ago 0 0 1 0 0 The 12-month price targets assessed by analysts reveal further insights, featuring an average target of $56.5, a high estimate of $62.00, and a low estimate of $50.00. This current average has increased by 16.49% from the previous average price target of $48.50. Analyzing Analyst Ratings: A Detailed Breakdown In examining recent analyst actions, we gain insights into how financial experts perceive Ingevity. The following summary outlines key analysts, their recent evaluations, and adjustments to ratings and price targets. Analyst Analyst Firm Action Taken Rating Current Price Target Prior Price Target Christopher Kapsch Loop Capital Raises Hold $56.00 $49.00 Ian Zaffino Oppenheimer Raises Outperform $58.00 $50.00 Daniel Rizzo Jefferies Raises Buy $62.00 $52.00 Michael Sison Wells Fargo Raises Equal-Weight $50.00 $43.00 Key Insights: Action Taken: Analysts respond to changes in market conditions and company performance, frequently updating their recommendations. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to Ingevity. This information offers a snapshot of how analysts perceive the current state of the company. Rating: Providing a comprehensive analysis, ...Full story available on Benzinga.com

The decline in sales of Ingevity (NGVT) is predominantly due to the repositioning of the Performance Chemicals unit in Q1.